Duvelisib targets vital tumorigenic routes by inhibiting the γ and δ isoforms of PI3K, which is not only directly toxic to tumour cells but also abrogates pro-survival cytokine and chemokine signalling in the tumour microenvironment.137. The gene discussed is PIK3CD; the disease is neoplasm.